<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113161</article-id><article-id pub-id-type="publisher-id">ACM-41045</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_81832257.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  术前系统免疫炎症指数和中性粒细胞/淋巴细胞比值与卵巢癌患者预后的关系
  The Prognostic Value of Systemic Immune-Inflammation Index and Neutrophil to Lymphocyte Ratio on the Prognosis of Ovarian Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>飞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>丁</surname><given-names>朝霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>爱平</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院妇产科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1125</fpage><lpage>1131</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨系统免疫炎症指数(SII)和外周血中性粒细胞/淋巴细胞计数比值(NLR)对卵巢癌患者无进展生存期(PFS)的评估价值。方法：回顾性分析2012年6月至2015年6月于青岛大学附属医院就诊123例卵巢癌患者的临床资料，应用受试者工作特征(ROC)曲线确定SII和NLR的最佳临界值，Kaplan-Meier生存曲线评估SII和NLR对卵巢癌PFS的影响。单因素和多因素分析确定影响卵巢癌PFS的预后因素。结果：卵巢癌患者中，根据ROC曲线确定SII和NLR的最佳临界值，SII和NLR高水平组的PFS显著低于SII和NLR低水平组(P &lt; 0.001)，高水平组与低水平组在年龄和病理类型上没有明显差异，但高水平组在分化程度和FIGO分期中期别更晚，更易发生淋巴结转移。COX多因素分析显示分化程度差、FIGO分期晚期、SII及NLR高水平为影响卵巢癌患者PFS的独立危险因素。结论：SII和NLR是影响卵巢癌患者PFS的独立因素，SII和NLR高水平提示预后不良，因此SII和NLR有潜能作为预测卵巢癌预后的新指标。
    Objective: The study aimed to investigate the prognostic value of systemic immune-inflammation index (SII) and neutrophil to lymphocyte ratio (NLR) in patients with ovarian cancer (OC). Method: A total of 123 OC patients were retrospectively analyzed from June 2012 to June 2015 in the Affiliated Hospital of Qingdao University. We use receiver operating characteristic (ROC) curve to calculate the optimal cut-off values for SII and NLR. Kaplan-Meier survival curve was used to estimate the association between SII, NLR and progression-free survival (PFS) among OC patients. Results: In OC patients, the PFS in high SII and NLR groups was significantly lower than low SII and NLR group (P &lt; 0.001). Age and history were not found to be different between high SII, NLR groups and low groups, while advanced FIGO stage, low grade and positive lymph node were associated with high SII and NLR groups. Advanced FIGO stage, high grade, high SII and NLR were evaluated as independent risk factors according to COX multivariate analysis. Conclusion: SII and NLR are independent factors for prognosis of OC patients, and increased SII and NLR are related to a poor prognosis. Therefore, SII and NLR are potential factors to predict the prognosis of OC patients. 
  
 
</p></abstract><kwd-group><kwd>系统免疫炎症指数，中性粒细胞和淋巴细胞比值，卵巢癌，无进展生存期, Systemic Immune-Inflammation Index</kwd><kwd> Neutrophil to Lymphocyte Ratio</kwd><kwd> Ovarian Cancer</kwd><kwd>
Progression-Free Survival</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨系统免疫炎症指数(SII)和外周血中性粒细胞/淋巴细胞计数比值(NLR)对卵巢癌患者无进展生存期(PFS)的评估价值。方法：回顾性分析2012年6月至2015年6月于青岛大学附属医院就诊123例卵巢癌患者的临床资料，应用受试者工作特征(ROC)曲线确定SII和NLR的最佳临界值，Kaplan-Meier生存曲线评估SII和NLR对卵巢癌PFS的影响。单因素和多因素分析确定影响卵巢癌PFS的预后因素。结果：卵巢癌患者中，根据ROC曲线确定SII和NLR的最佳临界值，SII和NLR高水平组的PFS显著低于SII和NLR低水平组(P &lt; 0.001)，高水平组与低水平组在年龄和病理类型上没有明显差异，但高水平组在分化程度和FIGO分期中期别更晚，更易发生淋巴结转移。COX多因素分析显示分化程度差、FIGO分期晚期、SII及NLR高水平为影响卵巢癌患者PFS的独立危险因素。结论：SII和NLR是影响卵巢癌患者PFS的独立因素，SII和NLR高水平提示预后不良，因此SII和NLR有潜能作为预测卵巢癌预后的新指标。</p></sec><sec id="s2"><title>关键词</title><p>系统免疫炎症指数，中性粒细胞和淋巴细胞比值，卵巢癌，无进展生存期</p></sec><sec id="s3"><title>The Prognostic Value of Systemic Immune-Inflammation Index and Neutrophil to Lymphocyte Ratio on the Prognosis of Ovarian Cancer</title><p>Fei Zhao<sup>*</sup>, Zhaoxia Ding, Aiping Chen<sup>#</sup></p><p>Obstetrics and Gynecology Department, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/44-1572016x5_hanspub.png" /></p><p>Received: Feb. 17<sup>th</sup>, 2021; accepted: Mar. 5<sup>th</sup>, 2021; published: Mar. 19<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/44-1572016x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: The study aimed to investigate the prognostic value of systemic immune-inflammation index (SII) and neutrophil to lymphocyte ratio (NLR) in patients with ovarian cancer (OC). Method: A total of 123 OC patients were retrospectively analyzed from June 2012 to June 2015 in the Affiliated Hospital of Qingdao University. We use receiver operating characteristic (ROC) curve to calculate the optimal cut-off values for SII and NLR. Kaplan-Meier survival curve was used to estimate the association between SII, NLR and progression-free survival (PFS) among OC patients. Results: In OC patients, the PFS in high SII and NLR groups was significantly lower than low SII and NLR group (P &lt; 0.001). Age and history were not found to be different between high SII, NLR groups and low groups, while advanced FIGO stage, low grade and positive lymph node were associated with high SII and NLR groups. Advanced FIGO stage, high grade, high SII and NLR were evaluated as independent risk factors according to COX multivariate analysis. Conclusion: SII and NLR are independent factors for prognosis of OC patients, and increased SII and NLR are related to a poor prognosis. Therefore, SII and NLR are potential factors to predict the prognosis of OC patients.</p><p>Keywords:Systemic Immune-Inflammation Index, Neutrophil to Lymphocyte Ratio, Ovarian Cancer, Progression-Free Survival</p><disp-formula id="hanspub.41045-formula12"><graphic xlink:href="//html.hanspub.org/file/44-1572016x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/44-1572016x8_hanspub.png" /> <img src="//html.hanspub.org/file/44-1572016x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>卵巢癌是女性生殖系统最常见的恶性肿瘤之一，其中最主要的组织学类型是上皮性卵巢癌，具有发病隐匿、转移和复发耐药等特点，死亡率居妇科恶性肿瘤的首位。虽然近年来卵巢癌的手术和辅助治疗手段显著提升，然而患者的5年生存率仍然徘徊在48%左右 [<xref ref-type="bibr" rid="hanspub.41045-ref1">1</xref>]。由于卵巢癌早期缺乏有效的筛查手段，将近70%的患者发现时已处于晚期。另外，晚期卵巢癌的复发和耐药一直是困扰临床的难题之一。因此，寻找有效的生物学指标来预测卵巢癌的预后并指导患者个体化治疗是必要的。</p><p>自1863年Virchow首次提出“淋巴细胞网状浸润”来解释肿瘤细胞起源于慢性炎症至今，炎症在肿瘤生长中所起到的作用被广泛接受 [<xref ref-type="bibr" rid="hanspub.41045-ref2">2</xref>]。炎性肿瘤微环境与肿瘤细胞之间的相互作用在肿瘤形成机制中扮演着重要角色，炎症细胞和各种促炎因子在肿瘤的发生、进展、侵袭和转移等各个阶段起到了至关重要的作用 [<xref ref-type="bibr" rid="hanspub.41045-ref3">3</xref>]。近年来的研究表明，术前外周血中性粒细胞与淋巴细胞计数的比值(Neutrophil-to-lymphocyte ratio, NLR)、血小板与淋巴细胞计数的比值(Platelet-to-lymphocyte ratio, PLR)是胰腺癌、肝癌和肾癌等多种实体肿瘤的预后指标，较高的NLR、PLR值提示肿瘤的预后不良 [<xref ref-type="bibr" rid="hanspub.41045-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41045-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.41045-ref6">6</xref>]。系统免疫炎症指数(Systemic immune-inflammation index, SII)是整合了中性粒细胞、血小板和淋巴细胞计数这三者的新模型，近年来逐渐被发现在肺癌、胃癌和食管癌等肿瘤的预后中具有预测价值 [<xref ref-type="bibr" rid="hanspub.41045-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.41045-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.41045-ref9">9</xref>]。目前，SII卵巢癌预后中的预测价值研究较少。本研究通过回顾性分析近年于青岛大学附属医院就诊并接受初次手术治疗的卵巢癌患者的临床资料，旨在探究SII和NLR在卵巢癌预后中的预测价值。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 临床资料</title><p>收集2012年6月~2015年6月在青岛大学附属医院初次行手术治疗的123例卵巢癌患者的临床病理资料。纳入标准：① 术前未行放疗和化疗；② 在我院初次行原发性肿瘤细胞减灭术和系统性淋巴结清扫术；③ 最终病理诊断为上皮性卵巢癌；④ 病例资料完善。排除标准：① 术前合并感染性、血液系统和自身免疫性疾病等可能影响炎性指标的患者；② 合并其他恶性肿瘤的患者；③ 有冠心病、脑血管病、肺栓塞等严重基础疾病的患者；④ 严重肝肾功能不全、服用免疫抑制剂的患者。本研究经青岛大学附属医院医学伦理委员会批准，所有患者均已知情并同意。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><p>1) 资料收集收集患者的临床病理特征，包括年龄、既往史、FIGO分期(2013年)、组织学类型、分化程度、双侧癌、淋巴结转移等。另外，需收集卵巢癌患者术前1周内的静脉血血常规的化验结果，记录血小板计数、中性粒细胞计数和淋巴细胞计数。分别计算NLR和SII数值。NLR=中性粒细胞计数/淋巴细胞计数 [<xref ref-type="bibr" rid="hanspub.41045-ref10">10</xref>]；SII = 中性粒细胞计数 &#215; 血小板计数/淋巴细胞计数 [<xref ref-type="bibr" rid="hanspub.41045-ref11">11</xref>]。</p><p>2) 随访方式术后定期随访，第1~2年每3个月复查一次，第3~5年每6个月复查一次，往后每年复查一次。复查的内容包括：肿瘤标志物、腹部和盆腔CT、胸部CT、妇科超声等，胸部CT至少每年复查一次。随访采用门诊复查、电话随访等方式，随访至复发或2020年6月。无进展生存期从手术时间算起，至首次复发时间或末次随访时间。</p></sec><sec id="s6_3"><title>2.3. 统计学方法</title><p>所有统计学分析采用SPSS 25.0软件进行操作。应用受试者工作特征(ROC)曲线确定NLR和SII分组的最佳临界值。采用卡方检验比较组间差异，应用Kaplan-Meier法计算累计生存曲线，Log-rank检验比较组间差异。单因素和多因素Cox回归模型分析预后的独立影响因素，P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 术前SII、NLR与卵巢癌临床病理特征的关系</title><p>根据ROC曲线计算出SII和NLR的最佳截断值分别为550.0和2.1。根据最佳截断值分为SII低水平组(SII &lt; 550.0, n = 52)和SII高水平组(SII ≥ 550.0, n = 71)、NLR低水平组(NLR &lt; 2.1, n = 47)和NLR高水平组(NLR ≥ 2.1, n = 76)。当SII ≥ 550.0时ROC曲线下面积为0.801，敏感性和特异性分别为72.1%、80%；当NLR ≥ 2.1时ROC曲线下面积为0.778，敏感性和特异性分别为78.4%、80%。SII高水平组与低水平组在年龄和病理类型上没有显著差异，但在分化程度、FIGO分期及淋巴结转移方面具有显著性差异，SII高水平组的分化程度及FIGO分期明显晚于低水平组，且更易发生淋巴结的转移。与SII分组结果类似，NLR高水平组与低水平组也在年龄和病理类型上没有明显差异，但NLR高水平组在分化程度和FIGO分期中期别更晚，更易发生淋巴结转移(表1)。</p></sec><sec id="s7_2"><title>3.2. 术前SII、NLR与卵巢癌患者无进展生存期的关系</title><p>本研究中123例卵巢癌患者的平均无进展生存期为40个月，SII高水平组与SII低水平组的中位生存时间分别为28个月和49个月，差异具有统计学意义(P &lt; 0.001)；NLR高水平组与NLR低水平组的中位生存时间分别为30个月和50个月，差异具有统计学意义(P &lt; 0.001) (图1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The correlation between preoperative SII and NLR with clinicopathological characteristics of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >变量</th><th align="center" valign="middle"  colspan="2"  >SII值</th><th align="center" valign="middle"  rowspan="2"  >c<sup>2</sup>值</th><th align="center" valign="middle"  colspan="2"   rowspan="2"  >P值</th><th align="center" valign="middle"  colspan="4"  >NLR值</th><th align="center" valign="middle"  rowspan="2"  >c<sup>2</sup>值</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >低水平</td><td align="center" valign="middle" >高水平</td><td align="center" valign="middle"  colspan="2"  >低水平</td><td align="center" valign="middle"  colspan="2"  >高水平</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;50</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >16</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.474</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.491</td><td align="center" valign="middle"  colspan="2"  >13</td><td align="center" valign="middle" >18</td><td align="center" valign="middle"  rowspan="2"  >0.004</td><td align="center" valign="middle"  rowspan="2"  >0.951</td></tr><tr><td align="center" valign="middle" >≥50</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >54</td><td align="center" valign="middle"  colspan="2"  >36</td><td align="center" valign="middle" >56</td></tr><tr><td align="center" valign="middle" >病理类型</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >非浆液性</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >33</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.174</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.676</td><td align="center" valign="middle"  colspan="2"  >25</td><td align="center" valign="middle" >35</td><td align="center" valign="middle"  rowspan="2"  >0.05</td><td align="center" valign="middle"  rowspan="2"  >0.823</td></tr><tr><td align="center" valign="middle" >浆液性</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >37</td><td align="center" valign="middle"  colspan="2"  >21</td><td align="center" valign="middle" >42</td></tr><tr><td align="center" valign="middle" >分化程度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >G1/G2</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >23</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >14.40</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >&lt;0.01</td><td align="center" valign="middle"  colspan="2"  >28</td><td align="center" valign="middle" >20</td><td align="center" valign="middle"  rowspan="2"  >8.53</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.01</td></tr><tr><td align="center" valign="middle" >G3</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >60</td><td align="center" valign="middle"  colspan="2"  >23</td><td align="center" valign="middle" >62</td></tr><tr><td align="center" valign="middle" >FIGO分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I/II</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >24</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >22.52</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >&lt;0.001</td><td align="center" valign="middle"  colspan="2"  >38</td><td align="center" valign="middle" >28</td><td align="center" valign="middle"  rowspan="2"  >20.60</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.001</td></tr><tr><td align="center" valign="middle" >III/IV</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >45</td><td align="center" valign="middle"  colspan="2"  >10</td><td align="center" valign="middle" >47</td></tr><tr><td align="center" valign="middle" >有无淋巴结转移</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >31</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >23.28</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >&lt;0.001</td><td align="center" valign="middle"  colspan="2"  >42</td><td align="center" valign="middle" >35</td><td align="center" valign="middle"  rowspan="2"  >12.7</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.001</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >39</td><td align="center" valign="middle"  colspan="2"  >10</td><td align="center" valign="middle" >36</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 术前SII和NLR与卵巢癌临床病理特征的关系</p><p>图1. 123例卵巢癌患者无进展生存曲线(Kaplan-Meier)</p></sec><sec id="s7_3"><title>3.3. 影响卵巢癌预后的COX单因素和多因素分析</title><p>将可能影响卵巢癌预后的因素进行COX单因素和多因素分析。结果显示，单因素分析中病理类型、分化程度、FIGO分期、淋巴结转移、SII及NLR高水平为影响卵巢癌无进展生存期的独立危险因素，而在多因素分析中，病理类型及淋巴结转移并非独立危险因素，分化程度、FIGO分期、SII及NLR高水平为影响卵巢癌无进展生存期的独立危险因素(表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Analysis of COX single and multiple factors affecting the prognosis of ovarian cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >变量</th><th align="center" valign="middle"  colspan="2"  >单因素分析</th><th align="center" valign="middle"  rowspan="2"  >P值</th><th align="center" valign="middle"  colspan="4"  >多因素分析</th><th align="center" valign="middle"  colspan="2"   rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >HR</td><td align="center" valign="middle" >95%CI</td><td align="center" valign="middle"  colspan="2"  >HR</td><td align="center" valign="middle"  colspan="2"  >95%CI</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;50</td><td align="center" valign="middle"  rowspan="2"  >1.015</td><td align="center" valign="middle"  rowspan="2"  >0.631~1.634</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.95</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.824</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.502~1.353</td><td align="center" valign="middle"  rowspan="2"  >0.444</td></tr><tr><td align="center" valign="middle" >≥50</td></tr><tr><td align="center" valign="middle" >病理类型</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >浆液性</td><td align="center" valign="middle"  rowspan="2"  >1.826</td><td align="center" valign="middle"  rowspan="2"  >1.187~2.808</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >&lt;0.01</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >1.286</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.780~2.118</td><td align="center" valign="middle"  rowspan="2"  >0.324</td></tr><tr><td align="center" valign="middle" >非浆液性</td></tr><tr><td align="center" valign="middle" >FIGO分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I/II</td><td align="center" valign="middle"  rowspan="2"  >4.137</td><td align="center" valign="middle"  rowspan="2"  >2.647~6.463</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >&lt;0.001</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >2.295</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >1.184~4.448</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.05</td></tr><tr><td align="center" valign="middle" >III/IV</td></tr><tr><td align="center" valign="middle" >分化程度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >G1/G2</td><td align="center" valign="middle"  rowspan="2"  >1.536</td><td align="center" valign="middle"  rowspan="2"  >1.133~2.083</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >&lt;0.01</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >1.419</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >1.020~1.974</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.05</td></tr><tr><td align="center" valign="middle" >G3</td></tr><tr><td align="center" valign="middle" >淋巴结转移</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle"  rowspan="2"  >3.851</td><td align="center" valign="middle"  rowspan="2"  >2.511~5.908</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >&lt;0.001</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >1.190</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >0.612~2.314</td><td align="center" valign="middle"  rowspan="2"  >0.608</td></tr><tr><td align="center" valign="middle" >无</td></tr><tr><td align="center" valign="middle" >SII</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;550</td><td align="center" valign="middle"  rowspan="2"  >3.340</td><td align="center" valign="middle"  rowspan="2"  >2.076~5.374</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >&lt;0.001</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >1.906</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >1.033~3.515</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.05</td></tr><tr><td align="center" valign="middle" >≥550</td></tr><tr><td align="center" valign="middle" >NLR</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle"  colspan="2"  ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;2.1</td><td align="center" valign="middle"  rowspan="2"  >4.088</td><td align="center" valign="middle"  rowspan="2"  >2.444~6.837</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >&lt;0.001</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >2.547</td><td align="center" valign="middle"  colspan="2"   rowspan="2"  >1.356~4.783</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.01</td></tr><tr><td align="center" valign="middle" >≥2.1</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 影响卵巢癌预后的COX单因素和多因素分析</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>炎症作为一个复杂的过程，包含了先天性和适应性免疫细胞的激活、募集和作用。肿瘤细胞、周围的基质和炎症细胞通过复杂而精细的相互作用共同构成了炎性肿瘤微环境 [<xref ref-type="bibr" rid="hanspub.41045-ref3">3</xref>]。淋巴细胞、中性粒细胞和巨噬细胞等免疫细胞被募集到肿瘤微环境中，巨噬细胞和中性粒细胞能够产生大量的活性氧和多种炎性因子 [<xref ref-type="bibr" rid="hanspub.41045-ref12">12</xref>]。肿瘤微环境中的细胞具有高度可塑性的特点，在活性氧和炎性因子等多种刺激下发生细胞基因突变和DNA损伤，持续改变表型和功能特征，导致肿瘤的生长和进展。近年来的研究显示，术前NLR和PLR值在多种实体肿瘤中可以作为预测肿瘤预后的指标。例如，M Stotz等人发现，在初次接受手术治疗的胰腺癌患者中，较高的NLR值提示预后不良 [<xref ref-type="bibr" rid="hanspub.41045-ref4">4</xref>]。除此之外，Yohei Mano等人的研究显示，在肝癌患者中，NLR高值组的5年生存率显著低于NLR低值组，对两组肝癌组织进行免疫组化染色，结果在NLR高值组中肿瘤相关巨噬细胞标志物——CD163阳性染色细胞数增多，提示NLR升高可能与肿瘤相关巨噬细胞有关 [<xref ref-type="bibr" rid="hanspub.41045-ref12">12</xref>]。2014年，Bo Hu等人首次将中性粒细胞、血小板和淋巴细胞计数整合在一起，构建了系统免疫炎症指数这个新的模型，并在肝癌中验证了SII能够作为预测肿瘤预后的指标 [<xref ref-type="bibr" rid="hanspub.41045-ref11">11</xref>]。随后多项研究证实了SII在多种实体肿瘤中的预测价值。</p><p>SII是血小板乘以中性粒细胞与淋巴细胞计数的比值，SII升高表明血小板和中性粒细胞计数相对升高或者淋巴细胞计数相对降低。血小板对肿瘤微环境中性粒细胞和巨噬细胞的募集具有重要的作用，外周血中血小板增多与肿瘤的不良预后相关 [<xref ref-type="bibr" rid="hanspub.41045-ref12">12</xref>]。有研究指出，血小板可以保护肿瘤细胞免受循环系统中的免疫攻击并为肿瘤扩散提供粘附位点，除此之外，血小板释放的多种趋化因子和血管内皮生长因子(VEGF)，能够为肿瘤募集大量的巨噬细胞和中性粒细胞，促进肿瘤血管生成 [<xref ref-type="bibr" rid="hanspub.41045-ref13">13</xref>]。中性粒细胞作为炎症或感染的第一道防线，也能够募集巨噬细胞和单核细胞，它释放的多种炎性因子阻断抗肿瘤的免疫力，使肿瘤微环境趋向于更有利于肿瘤细胞生长的状态 [<xref ref-type="bibr" rid="hanspub.41045-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.41045-ref14">14</xref>]。淋巴细胞能够特异性识别并杀伤肿瘤细胞，并能够释放多种细胞因子激活抗肿瘤的免疫，循环系统中淋巴细胞减少说明机体抗肿瘤能力降低，肿瘤得以生长和进展。</p><p>炎症在卵巢癌的发生、发展和转移中扮演着至关重要的角色。卵巢癌肿瘤微环境中的肿瘤细胞和炎性细胞能够分泌多种细胞因子对抗凋亡、促进血管形成、肿瘤生长和转移 [<xref ref-type="bibr" rid="hanspub.41045-ref15">15</xref>]。炎症与卵巢癌的关系极为紧密，通过炎症细胞来预测卵巢癌的预后也成为研究的热点。Yi Miao等人的研究表明，NLR、PLR低值组患者的肿瘤PFS和OS更长 [<xref ref-type="bibr" rid="hanspub.41045-ref16">16</xref>]。另外，Dan Nie等人发现SII高值组的FIGO分期显著晚于低值组，且易发生淋巴结转移，而SII低值组比高值组的患者有更长的PFS和OS [<xref ref-type="bibr" rid="hanspub.41045-ref17">17</xref>]。我们的研究结果显示SII和NLR高水平组患者的PFS较低水平组显著降低，差异具有统计学意义。SII、NLR高水平组在分化程度、FIGO分期方面明显晚于低水平组，更易发生淋巴结转移。另外，COX多因素分析提示FIGO分期为晚期、肿瘤分化程度差、SII和NLR高水平是影响卵巢癌预后的独立危险因素。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，术前SII和NLR是影响卵巢癌预后的独立危险因素。两者的值越高，可能提示卵巢癌预后越差。血常规为每一位患者入院后的必查项目，简便快捷且价格低廉。SII和NLR可以通过血常规中的血小板、中性粒细胞和淋巴细胞计数获得，可用于临床上筛选出高危患者，制定个体化治疗方案，提高患者预后。</p></sec><sec id="s10"><title>基金项目</title><p>青岛大学“临床医学 + X”科研项目(2017M21)。</p></sec><sec id="s11"><title>文章引用</title><p>赵 飞,丁朝霞,陈爱平. 术前系统免疫炎症指数和中性粒细胞/淋巴细胞比值与卵巢癌患者预后的关系The Prognostic Value of Systemic Immune-Inflammation Index and Neutrophil to Lymphocyte Ratio on the Prognosis of Ovarian Cancer[J]. 临床医学进展, 2021, 11(03): 1125-1131. https://doi.org/10.12677/ACM.2021.113161</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41045-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30.  
&lt;br&gt;https://doi.org/10.3322/caac.21590</mixed-citation></ref><ref id="hanspub.41045-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Balkwill, F. and Mantovani, A. (2001) Inflammation and Cancer: Back to Virchow? The Lancet, 357, 539-545.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(00)04046-0</mixed-citation></ref><ref id="hanspub.41045-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Greten, F.R. and Grivennikov, S.I. (2019) Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity, 51, 27-41. &lt;br&gt;https://doi.org/10.1016/j.immuni.2019.06.025</mixed-citation></ref><ref id="hanspub.41045-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Stotz, M., Gerger, A., Eisner, F., et al. (2013) Increased Neutrophil-Lymphocyte Ratio Is a Poor Prognostic Factor in Patients with Primary Operable and Inoperable Pancreatic Cancer. British Journal of Cancer, 109, 416-421.  
&lt;br&gt;https://doi.org/10.1038/bjc.2013.332</mixed-citation></ref><ref id="hanspub.41045-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Uchinaka, E.I., Amisaki, M., Yagyu, T., et al. (2019) Prognostic Significance of Pre-Surgical Combined Platelet Count and Neutrophil-Lymphocyte Ratio for Patients with Hepatocellular Carcinoma. In Vivo, 33, 2241-2248.  
&lt;br&gt;https://doi.org/10.21873/invivo.11729</mixed-citation></ref><ref id="hanspub.41045-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Pedersen, M.M., Donskov, F., Pedersen, L., et al. (2020) Elevated Neutrophil-Lymphocyte Ratio Combined with Hyponatremia Indicate Poor Prognosis in Renal Cell Carcinoma. Acta Oncologica, 59, 13-19.  
&lt;br&gt;https://doi.org/10.1080/0284186X.2019.1654128</mixed-citation></ref><ref id="hanspub.41045-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Berardi, R., Santoni, M., Rinaldi, S., et al. (2019) Pre-Treatment Systemic Immune-Inflammation Represents a Prognostic Factor in Patients with Advanced Non-Small Cell Lung Cancer. Annals of Translational Medicine, 7, 572.  
&lt;br&gt;https://doi.org/10.21037/atm.2019.09.18</mixed-citation></ref><ref id="hanspub.41045-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L., Wang, C., Wang, J., et al. (2017) A Novel Systemic Immune-Inflammation Index Predicts Survival and Quality of Life of Patients after Curative Resection for Esophageal Squamous Cell Carcinoma. Journal of Cancer Research and Clinical Oncology, 143, 2077-2086. &lt;br&gt;https://doi.org/10.1007/s00432-017-2451-1</mixed-citation></ref><ref id="hanspub.41045-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Chen, L., Yan, Y., Zhu, L., et al. (2017) Systemic Immune-Inflammation Index as a Useful Prognostic Indicator Predicts Survival in Patients with Advanced Gastric Cancer Treated with Neoadjuvant Chemotherapy. Cancer Management and Research, 9, 849-867. &lt;br&gt;https://doi.org/10.2147/CMAR.S151026</mixed-citation></ref><ref id="hanspub.41045-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Mano, Y., Shirabe, K., Yamashita, Y., et al. (2013) Preoperative Neutrophil-to-Lymphocyte Ratio Is a Predictor of Survival after Hepatectomy for Hepatocellular Carcinoma: A Retrospective Analysis. Annals of Surgery, 258, 301-305.  
&lt;br&gt;https://doi.org/10.1097/SLA.0b013e318297ad6b</mixed-citation></ref><ref id="hanspub.41045-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Hu, B., Yang, X.R., Xu, Y., et al. (2014) Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 20, 6212-6222.  
&lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-14-0442</mixed-citation></ref><ref id="hanspub.41045-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kim, J. and Bae, J.S. (2016) Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators of Inflammation, 2016, Article ID: 6058147. &lt;br&gt;https://doi.org/10.1155/2016/6058147</mixed-citation></ref><ref id="hanspub.41045-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Gay, L.J. and Felding-Habermann, B. (2011) Contribution of Platelets to Tumour Metastasis. Nature Reviews Cancer, 11, 123-134. &lt;br&gt;https://doi.org/10.1038/nrc3004</mixed-citation></ref><ref id="hanspub.41045-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Cools-Lartigue, J., Spicer, J., McDonald, B., et al. (2013) Neutrophil Extracellular Traps Sequester Circulating Tumor Cells and Promote Metastasis. Journal of Clinical Investigation, 123, 3446-3458.</mixed-citation></ref><ref id="hanspub.41045-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Browning, L., Patel, M.R., Horvath, E.B., et al. (2018) IL-6 and Ovarian Cancer: Inflammatory Cytokines in Promotion of Metastasis. Cancer Management and Research, 10, 6685-6693. &lt;br&gt;https://doi.org/10.2147/CMAR.S179189</mixed-citation></ref><ref id="hanspub.41045-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Miao, Y., Yan, Q., Li, S., et al. (2016) Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Are Predictive of Chemotherapeutic Response and Prognosis in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy. Cancer Biomarkers, 17, 33-40. &lt;br&gt;https://doi.org/10.3233/CBM-160614</mixed-citation></ref><ref id="hanspub.41045-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Nie, D., Gong, H., Mao, X. and Li, Z. (2019) Systemic Immune-Inflammation Index Predicts Prognosis in Patients with Epithelial Ovarian Cancer: A Retrospective Study. Gynecologic Oncology, 152, 259-264.  
&lt;br&gt;https://doi.org/10.1016/j.ygyno.2018.11.034</mixed-citation></ref></ref-list></back></article>